Digital Therapeutics
Software that works like medicine. These companies are creating clinically validated digital tools that treat and manage diseases just like traditional pharmaceuticals, but with the scalability of technology. Professional investors see enormous potential in this rapidly evolving healthcare frontier.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
DARIOHEALTH CORP
DRIO
Current price
$0.57
The company provides a global digital therapeutics (DTx) platform with personalized interventions for chronic conditions like diabetes and hypertensio...
The company provides a global digital therapeutics (DTx) platform with personalized interventions for chronic conditions like diabetes and hypertension.
Teladoc Inc
TDOC
Current price
$7.34
As a major provider of virtual healthcare, its services include chronic condition management and mental health support delivered via its digital platf...
As a major provider of virtual healthcare, its services include chronic condition management and mental health support delivered via its digital platform.
Hims & Hers Health Inc
HIMS
Current price
$42.18
The company's consumer-first platform provides access to treatments for various chronic conditions via digital prescriptions and cloud pharmacy fulfil...
The company's consumer-first platform provides access to treatments for various chronic conditions via digital prescriptions and cloud pharmacy fulfillment.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
Digital therapeutics represents the next evolution in healthcare, where FDA-cleared software serves as medicine itself. These companies create evidence-based interventions delivered directly to patients via apps and platforms, transforming treatment for chronic diseases, mental health conditions, and more.
What You Need to Know
This portfolio spans the digital health ecosystem, from specialized software developers to telehealth platforms and supportive technologies. A key catalyst is growing regulatory acceptance and new reimbursement pathways, validating both the clinical effectiveness and commercial potential of these innovations.
Why These Stocks
We've selected companies whose primary business involves creating software-based medical interventions, ensuring direct exposure to this innovative field. Many are seeing increasing insurance coverage decisions, which is critical for widespread adoption and long-term revenue growth.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+198.45%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 198.45% over the next year.
Stocks Rated Buy by Analysts
9 of 12 assets in this group are rated Buy by professional analysts.
Group Growth vs Bank interest
This group averaged a 32% return last month, beating the typical 4% bank rate.
Why You'll Want to Watch These Stocks
Software is Becoming Medicine
These companies are creating FDA-cleared apps that actually treat diseases—not just track symptoms. It's an entirely new category of medicine with massive growth potential.
Insurance Companies are Paying
A major catalyst is happening right now: insurers are increasingly covering these digital treatments, unlocking billions in potential revenue that wasn't accessible before.
Early Stage with Big Backers
Major pharmaceutical companies and healthcare systems are partnering with these innovators, signaling their belief in the technology's transformative potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Frequently Asked Questions
Everything you need to know about the product and billing.